Investor's Business Daily on MSN
Stocks with rising relative strength: Denali Therapeutics
A Relative Strength Rating upgrade for Denali Therapeutics shows improving technical performance. Will it continue?
Denali Therapeutics (DNLI) drew fresh interest after publishing Phase 1/2 trial results for its Hunter syndrome therapy, ...
Denali Therapeutics announced that results from its open-label Phase 1/2 trial of tividenofusp alfa for Hunter syndrome were published in the January 1, 2026 issue of The New England Journal of ...
Zacks Investment Research on MSN
Denali Therapeutics unveils portfolio goals for 2026, stock up
Denali Therapeutics Inc. DNLI recently outlined its roadmap for 2026 across its portfolio of investigational therapies for ...
Tividenofusp alfa treatment showed reduction and normalization in key disease biomarkers, stabilization or improvement in clinical endpoints ...
Preparing for FDA approval and commercial launch of tividenofusp alfa, Denali’s TransportVehicle™ (TV)-enabled investigational therapy for Hunter ...
A common sentiment in Alaska is that while President Donald Trump has ordered the name of North America’s tallest peak to be changed from Denali to McKinley, Alaskans will call it what they want. And ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback